expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
Published 2 years ago • 395 plays • Length 1:13:00Download video MP4
Download video MP3
Similar videos
-
1:32:38
managed care implications of the expanding role of parp inhibitors in oncology
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
1:14:57
embracing progress, transforming treatment, empowering patients
-
1:33:57
evaluating the evidence and parsing the practicalities of therapeutic choices in hr breast cancer
-
1:08
using parp inhibitors to improve quality of life for patients with metastatic breast cancer
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
1:27:32
target practice: understanding how parp inhibitors take aim at ddr mutations across solid tumors
-
4:02
talking with patients about parp inhibitors for breast cancer
-
3:58
brca breast cancer: the advent of parp inhibitors
-
1:16
parp inhibitors improve outcomes, qol in breast cancer
-
58:12
enhancing personalized medicine in ovarian cancer: advances in parp inhibition and novel modalities
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
16:25
what's new for hereditary breast cancer treatment?
-
2:47
talave: induction talazoparib with parp inhibition in breast cancer